TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Clearside Biomedical ( (CLSD) ).
On November 23, 2025, Clearside Biomedical filed for Chapter 11 bankruptcy to facilitate a strategic sale of its assets, aiming to maximize stakeholder value. The company will operate as a debtor-in-possession while seeking court approval for an auction process. Subsequently, on November 24, 2025, Nasdaq notified Clearside of its impending delisting due to non-compliance with listing requirements, with trading expected to shift to the over-the-counter market on December 1, 2025.
The most recent analyst rating on (CLSD) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.
Spark’s Take on CLSD Stock
According to Spark, TipRanks’ AI Analyst, CLSD is a Underperform.
Clearside Biomedical’s overall stock score is significantly impacted by its poor financial performance, with declining revenues and negative equity. The technical analysis further indicates a bearish market sentiment, and the valuation metrics reflect a lack of profitability. These factors collectively contribute to a low stock score.
To see Spark’s full report on CLSD stock, click here.
More about Clearside Biomedical
Clearside Biomedical, Inc. is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through its proprietary suprachoroidal space (SCS®) injection platform. The company offers products like the SCS Microinjector® and XIPERE® for treating retinal diseases such as neovascular age-related macular degeneration and diabetic retinopathy. Clearside also engages in licensing collaborations and has a pipeline of small molecule product candidates.
Average Trading Volume: 131,492
Technical Sentiment Signal: Sell
Current Market Cap: $4.71M
For an in-depth examination of CLSD stock, go to TipRanks’ Overview page.